ISSUE 98 I SEPTEMBER 2020

In association with

pause for

thought

Puberty blockers are a reversable intervention option for trans youths, so why are they so controversial?

NCTC: A century of cultures 

Why pharma loves crab blood

Can AI own drug patents?

NCTC: A century of cultures

Why pharma loves crab blood

Can AI own drug patents?
08/24/2020 06:19:41
  • Home | Pause for thought
  • In this issue
  • NSF
  • Contents
  • Datwyler Company Insight
  • Datwyler
  • News
  • Baxter
  • Covid-19 executive briefing by GlobalData
  • ELPRO Monitoring Solutions
  • Abivax’s ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for success
  • Abiomed’s Impella receives FDA Emergency Use Authorization during Covid-19
  • Fargo
  • Disruptions to global oncology trials have fallen to a three-month low
  • Mimotopes
  • AstraZeneca/Oxford University and CanSino publish promising Covid-19 vaccine cli
  • Biotech IPO valuation relies on data to enter capital markets during Covid-19 pa
  • Nelson Labs
  • The pharma industry briefing
  • Pfeiffer Vacuum
  • A century of cultures: celebrating the world’s oldest lab culture collection
  • Skyepharma
  • Gut feeling: exploring the therapeutic potential of the gut-brain axis
  • Optel
  • Crabby concoctions: why pharma’s thirst for crustacean blood is up for debate
  • Air France
  • Debunking myths about puberty blockers for transgender children
  • Micronova
  • Hiring from home: pharma recruitment in the age of Covid-19
  • Nipro Pharmapackaging
  • Q&A: breaking new ground in pharma packaging with Honeywell
  • Wipotec
  • Treatment-resistant rare diseases: exploring landmark drug approvals in 2020
  • VEGA Company Insight
  • VEGA Australia
  • Modernising pharma patents: can AI be an inventor?
  • ILC Dover
  • Boosting agility to accelerate project timescales
  • Scandinavian Health
  • Doing the right thing: the enhanced case for compliance
  • Deals in brief powered by GlobalData
  • The key list powered by GlobalData
  • Global markets and indices powered by GlobalData
  • Macro-economic indicators (1 of 2) powered by GlobalData
  • Macro-economic indicators (2 of 2) powered by GlobalData
  • Events
  • Next issue